Michael Null Named President Of Aurora Research Institute

PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Aurora Diagnostics announced today the appointment of Michael Null as the first president of the Aurora Research Institute, a division of Aurora dedicated to partnering with institutions to advance medical research. Mr. Null will report directly to Aurora Diagnostics Chairman, Chief Executive Officer and President Daniel D. Crowley.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.

Janssen has sent off its mutation-specific non-small cell lung cancer drug amivantamab to the FDA.